Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer.

Weidle UH, Birzele F, Nopora A.

Cancer Genomics Proteomics. 2019 Mar-Apr;16(2):99-119. doi: 10.21873/cgp.20116. Review.

2.

The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs.

Weidle UH, Epp A, Birzele F, Brinkmann U.

Cancer Genomics Proteomics. 2019 Jan-Feb;16(1):1-19. doi: 10.21873/cgp.20108. Review.

3.

LST1: A multifunctional gene encoded in the MHC class III region.

Weidle UH, Rohwedder I, Birzele F, Weiss EH, Schiller C.

Immunobiology. 2018 Nov;223(11):699-708. doi: 10.1016/j.imbio.2018.07.018. Epub 2018 Jul 17. Review.

PMID:
30055863
4.

Potential of Protein-based Anti-metastatic Therapy with Serpins and Inter α-Trypsin Inhibitors.

Weidle UH, Birzele F, Tiefenthaler G.

Cancer Genomics Proteomics. 2018 Jul-Aug;15(4):225-238. doi: 10.21873/cgp.20081. Review.

5.

The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets.

Weidle UH, Dickopf S, Hintermair C, Kollmorgen G, Birzele F, Brinkmann U.

Cancer Genomics Proteomics. 2018 Jan-Feb;15(1):17-39. Review.

6.

Potential microRNA-related Targets for Therapeutic Intervention with Ovarian Cancer Metastasis.

Weidle UH, Birzele F, Kollmorgen G, Nopora A.

Cancer Genomics Proteomics. 2018 Jan-Feb;15(1):1-15. Review.

7.

Long Non-coding RNAs and their Role in Metastasis.

Weidle UH, Birzele F, Kollmorgen G, Rüger R.

Cancer Genomics Proteomics. 2017 May-Jun;14(3):143-160. Review.

8.

The Multiple Roles of Exosomes in Metastasis.

Weidle UH, Birzele F, Kollmorgen G, Rüger R.

Cancer Genomics Proteomics. 2017 Jan 2;14(1):1-15. Review.

9.

Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.

Weidle UH, Birzele F, Kollmorgen G, Rueger R.

Cancer Genomics Proteomics. 2016 11-12;13(6):407-423. Review.

10.

Dissection of the Process of Brain Metastasis Reveals Targets and Mechanisms for Molecular-based Intervention.

Weidle UH, Birzele F, Kollmorgen G, Rüger R.

Cancer Genomics Proteomics. 2016 Jul-Aug;13(4):245-58. Review.

PMID:
27365375
11.

Molecular Basis of Lung Tropism of Metastasis.

Weidle UH, Birzele F, Kollmorgen G, Rüger R.

Cancer Genomics Proteomics. 2016 Mar-Apr;13(2):129-39. Review.

PMID:
26912803
12.

Molecular Mechanisms of Bone Metastasis.

Weidle UH, Birzele F, Kollmorgen G, Rüger R.

Cancer Genomics Proteomics. 2016 Jan-Feb;13(1):1-12. Review.

PMID:
26708594
13.

The Blood-Brain Barrier Challenge for the Treatment of Brain Cancer, Secondary Brain Metastases, and Neurological Diseases.

Weidle UH, Niewöhner J, Tiefenthaler G.

Cancer Genomics Proteomics. 2015 Jul-Aug;12(4):167-77. Review.

PMID:
26136217
14.

Molecular targets and pathways involved in liver metastasis of colorectal cancer.

Weidle UH, Birzele F, Krüger A.

Clin Exp Metastasis. 2015 Aug;32(6):623-35. doi: 10.1007/s10585-015-9732-3. Epub 2015 Jun 24. Review.

PMID:
26104118
15.

Tumor-antigen-binding bispecific antibodies for cancer treatment.

Weidle UH, Kontermann RE, Brinkmann U.

Semin Oncol. 2014 Oct;41(5):653-60. doi: 10.1053/j.seminoncol.2014.08.004. Epub 2014 Aug 12. Review.

16.

TCR-MHC/peptide interaction: prospects for new anti-tumoral agents.

Weidle UH, Georges G, Tiefenthaler G.

Cancer Genomics Proteomics. 2014 Nov-Dec;11(6):267-77. Review.

PMID:
25422358
17.

An upstream open reading frame regulates LST1 expression during monocyte differentiation.

Schiller C, Nowak C, Diakopoulos KN, Weidle UH, Weiss EH.

PLoS One. 2014 May 9;9(5):e96245. doi: 10.1371/journal.pone.0096245. eCollection 2014.

18.

Proteases as activators for cytotoxic prodrugs in antitumor therapy.

Weidle UH, Tiefenthaler G, Georges G.

Cancer Genomics Proteomics. 2014 Mar-Apr;11(2):67-79. Review.

PMID:
24709544
19.

Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer.

Weidle UH, Tiefenthaler G, Schiller C, Weiss EH, Georges G, Brinkmann U.

Cancer Genomics Proteomics. 2014 Jan-Feb;11(1):25-38. Review.

PMID:
24633317
20.

The translational potential for target validation and therapy using intracellular antibodies in oncology.

Weidle UH, Maisel D, Brinkmann U, Tiefenthaler G.

Cancer Genomics Proteomics. 2013 Nov-Dec;10(6):239-50. Review.

PMID:
24336633
21.

The emerging role of new protein scaffold-based agents for treatment of cancer.

Weidle UH, Auer J, Brinkmann U, Georges G, Tiefenthaler G.

Cancer Genomics Proteomics. 2013 Jul-Aug;10(4):155-68. Review.

PMID:
23893924
22.

The intriguing options of multispecific antibody formats for treatment of cancer.

Weidle UH, Tiefenthaler G, Weiss EH, Georges G, Brinkmann U.

Cancer Genomics Proteomics. 2013 Jan-Feb;10(1):1-18. Review.

PMID:
23382582
23.

LST1 promotes the assembly of a molecular machinery responsible for tunneling nanotube formation.

Schiller C, Diakopoulos KN, Rohwedder I, Kremmer E, von Toerne C, Ueffing M, Weidle UH, Ohno H, Weiss EH.

J Cell Sci. 2013 Feb 1;126(Pt 3):767-77. doi: 10.1242/jcs.114033. Epub 2012 Dec 13.

24.

Genetically engineered fusion proteins for treatment of cancer.

Weidle UH, Schneider B, Georges G, Brinkmann U.

Cancer Genomics Proteomics. 2012 Nov;9(6):357-72. Review.

PMID:
23162075
25.

Fully human targeted cytotoxic fusion proteins: new anticancer agents on the horizon.

Weidle UH, Georges G, Brinkmann U.

Cancer Genomics Proteomics. 2012 May-Jun;9(3):119-33. Review.

PMID:
22593247
26.

Upregulation of Trop-2 quantitatively stimulates human cancer growth.

Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, Lattanzio R, de Lange R, Weidle UH, Piantelli M, Alberti S.

Oncogene. 2013 Jan 10;32(2):222-33. doi: 10.1038/onc.2012.36. Epub 2012 Feb 20.

PMID:
22349828
27.

Differential splicing generates new transmembrane receptor and extracellular matrix-related targets for antibody-based therapy of cancer.

Weidle UH, Maisel D, Klostermann S, Weiss EH, Schmitt M.

Cancer Genomics Proteomics. 2011 Sep-Oct;8(5):211-26. Review.

PMID:
21980036
28.

Synthetic lethality-based targets for discovery of new cancer therapeutics.

Weidle UH, Maisel D, Eick D.

Cancer Genomics Proteomics. 2011 Jul-Aug;8(4):159-71. Review.

PMID:
21737609
29.

Full-length L1CAM and not its Δ2Δ27 splice variant promotes metastasis through induction of gelatinase expression.

Hauser S, Bickel L, Weinspach D, Gerg M, Schäfer MK, Pfeifer M, Hazin J, Schelter F, Weidle UH, Ramser J, Volkmann J, Meindl A, Schmitt M, Schrötzlmair F, Altevogt P, Krüger A.

PLoS One. 2011 Apr 25;6(4):e18989. doi: 10.1371/journal.pone.0018989.

30.

Intracellular proteins displayed on the surface of tumor cells as targets for therapeutic intervention with antibody-related agents.

Weidle UH, Maisel D, Klostermann S, Schiller C, Weiss EH.

Cancer Genomics Proteomics. 2011 Mar-Apr;8(2):49-63. Review. Erratum in: Cancer Genomics Proteomics. 2011 May-Jun;8(3):157.

PMID:
21471515
31.

Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer.

Weidle UH, Klostermann S, Eggle D, Krüger A.

Cancer Genomics Proteomics. 2010 Nov-Dec;7(6):287-302. Review.

PMID:
21156962
32.

ALCAM/CD166: cancer-related issues.

Weidle UH, Eggle D, Klostermann S, Swart GW.

Cancer Genomics Proteomics. 2010 Sep-Oct;7(5):231-43. Review.

PMID:
20952758
33.

Cancer-related issues of CD147.

Weidle UH, Scheuer W, Eggle D, Klostermann S, Stockinger H.

Cancer Genomics Proteomics. 2010 May-Jun;7(3):157-69. Review.

PMID:
20551248
34.

L1-CAM as a target for treatment of cancer with monoclonal antibodies.

Weidle UH, Eggle D, Klostermann S.

Anticancer Res. 2009 Dec;29(12):4919-31. Review.

35.

Cell growth stimulation by CRASH, an asparaginase-like protein overexpressed in human tumors and metastatic breast cancers.

Weidle UH, Evtimova V, Alberti S, Guerra E, Fersis N, Kaul S.

Anticancer Res. 2009 Apr;29(4):951-63.

36.

Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells.

Kohlhof H, Hampel F, Hoffmann R, Burtscher H, Weidle UH, Hölzel M, Eick D, Zimber-Strobl U, Strobl LJ.

Blood. 2009 May 28;113(22):5506-15. doi: 10.1182/blood-2008-11-190090. Epub 2009 Apr 1.

PMID:
19339697
37.

TGF-beta-induced apoptosis in endothelial cells mediated by M6P/IGFII-R and mini-plasminogen.

Leksa V, Godar S, Schiller HB, Fuertbauer E, Muhammad A, Slezakova K, Horejsi V, Steinlein P, Weidle UH, Binder BR, Stockinger H.

J Cell Sci. 2005 Oct 1;118(Pt 19):4577-86.

38.

Urokinase receptor antagonists: novel agents for the treatment of cancer.

Weidle UH, König B.

Expert Opin Investig Drugs. 1998 Mar;7(3):391-403.

PMID:
15991980
39.
40.

Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays.

de Wit NJ, Rijntjes J, Diepstra JH, van Kuppevelt TH, Weidle UH, Ruiter DJ, van Muijen GN.

Br J Cancer. 2005 Jun 20;92(12):2249-61.

41.

Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens.

Euer NI, Kaul S, Deissler H, Möbus VJ, Zeillinger R, Weidle UH.

Oncol Rep. 2005 Mar;13(3):375-87.

PMID:
15706405
42.

Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line.

Schlosser I, Hölzel M, Hoffmann R, Burtscher H, Kohlhuber F, Schuhmacher M, Chapman R, Weidle UH, Eick D.

Oncogene. 2005 Jan 13;24(3):520-4.

PMID:
15516975
43.

The MMA1 gene family of cancer-testis antigens has multiple alternative splice variants: characterization of their expression profile, the genomic organization, and transcript properties.

de Wit NJ, Cornelissen IM, Diepstra JH, Weidle UH, Ruiter DJ, van Muijen GN.

Genes Chromosomes Cancer. 2005 Jan;42(1):10-21.

PMID:
15472897
44.

Ectopic expression of DICE1 suppresses tumor cell growth.

Wieland I, Sell C, Weidle UH, Wieacker P.

Oncol Rep. 2004 Aug;12(2):207-11.

PMID:
15254679
45.

Identification of a Novel Transmembrane Protein (UKW): Association with Invasive Status of Mammary Carcinoma Cell Lines and Expression in Pancreatic Carcinoma.

Lösch S, Buchholz M, Gress TM, Weidle UH.

Cancer Genomics Proteomics. 2004 Jul-Aug;1(4):263-274. Epub 2004 Jul 1.

46.

Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis.

van Kempen LC, Meier F, Egeblad M, Kersten-Niessen MJ, Garbe C, Weidle UH, Van Muijen GN, Herlyn M, Bloemers HP, Swart GW.

J Invest Dermatol. 2004 May;122(5):1293-301.

47.

SMAGP, a new small trans-membrane glycoprotein altered in cancer.

Tarbé NG, Rio MC, Weidle UH.

Oncogene. 2004 Apr 22;23(19):3395-403.

PMID:
15021913
48.

LKW, a Putative Dual-specificity Kinase which is Down-regulated in Several Invasive Systems.

Lösch S, Buchholz M, Gress TM, Weidle UH.

Cancer Genomics Proteomics. 2004 Mar-Apr;1(2):177-188. Epub 2004 Mar 1.

49.

Identification of CRASH, a gene deregulated in gynecological tumors.

Evtimova V, Zeillinger R, Kaul S, Weidle UH.

Int J Oncol. 2004 Jan;24(1):33-41.

PMID:
14654938
50.

Supplemental Content

Loading ...
Support Center